Palabras clave
Diabetes mellitus tipo II
Metformina
SARS-CoV-2
Cómo citar
Copyright © | Todos los derechos reservados.
La revista posee los derechos de autor exclusivos para la publicación de este artículo en los términos de la ley brasileña 9610/98.
Reproducción parcial
El uso de partes de los textos, figuras y cuestionario del artículo es libre, siendo obligatoria la citación de los autores y revista.
Reproducción total
Está expresamente prohibido y debe ser autorizado por la revista.
Resumen
Objetivo: Estudiar la relación entre la disminución de la gravedad y la mortalidad de los pacientes diabéticos, usuarios de metformina, con COVID-19 grave en el ámbito hospitalario Métodos: Se trata de una investigación bibliográfica de relevancia científica de carácter integrador, observacional, transversal, comparativo, de carácter cuantitativo. Para la selección de artículos se realizó una búsqueda de la bibliografía digital que aborda el tema de estudio, en la base de datos de la Biblioteca Nacional de Medicina (PubMed). Resultados: Se demostró que la metformina es eficaz para mejorar el cuadro clínico en pacientes diabéticos hospitalizados con diagnóstico de COVID-19. En 50 estudios seleccionados, 23 demostraron que la metformina tiene diferentes acciones, las cuales son antiinflamatoria, inmunomoduladora e impidiendo la entrada del SARS-CoV-2 a la célula diana, a través del bloqueo del receptor ACE2, resultando en una respuesta positiva en el reducción de la gravedad y mortalidad de estos pacientes. Consideraciones finales: Varios estudios muestran una relación beneficiosa del uso de metformina en pacientes diabéticos y diagnosticados con COVID-19, con una reducción significativa en la severidad de la enfermedad viral, especialmente en el cuadro clínico de los pacientes, donde en la mayoría de los casos, existe no hubo evolución a SDRA ni aumento de las tasas de mortalidad.
Referencias
ABDI A, et al. Diabetes and COVID-19: a systematic review on the current evidences. Diabetes Research and Clinical Practice, 2020; 75(4): 1-14.
AL-KURAISHY HM, et al. COVID-19 and risk of acute ischemic stroke and acute lung injury in patients with type II diabetes mellitus: the anti-inflammatory role of metformin. Frontiers in Medicine, 2021; 8(2021): 1-10.
AZEVEDO MCA, et al. Relação fisiopatológica entre Covid-19 e diabetes mellitus tipo 2: uma revisão narrativa. Revista Eletrônica Acervo Saúde, 2022; 15(4): e10154.
BRASIL. 2014. In: Ministério da Saúde. 57,4 milhões de brasileiros têm pelo menos uma doença crônica. Disponível em: https://www.unasus.gov.br/noticia/574-milhoes-de-brasileiros-tem-pelo-menos-uma-doenca-cronica. Acessado em: 31 de maio de 2022.
BRASIL. 2020. Ministério da Saúde (MS). Saúde de A a Z. 2020, 2020. Disponível em: https://bvsms.saude.gov.br/diabetes/. Acessado em: 24 de outubro de 2022.
CASTRO RMF, et al. Diabetes mellitus e suas complicações-uma revisão sistemática e informativa. Brazilian Journal of Health Review, 2021; 4(1): 3349-3391.
CHENG X, et al. Effects of metformin, insulin on COVID-19 patients with pre-existed type 2 diabetes: a multicentral retrospective study. Life Sciences, 2021; 275(2021): 1-10.
CROUSE AB, et al. Metformin use is associated with reduced mortality in a diverse population with COVID-19 and diabetes. Frontiers in Endocrinology, 2021; 11(600439): 1-8.
GHANY R, et al. Metformin is associated with lower hospitalizations, mortality and severe coronavirus infection among elderly medicare minority patients in 8 states in USA. Diabetes & Metabolic Syndrome: Clinical Research & Reviews, 2021; 15(2): 513-518.
IBRAHIM S, et al. Metformin and covid-19: focused review of mechanisms and current literature suggesting benefit. Frontiers in Endocrinology, 2021; 12(587801): 1-11.
INTERNATIONAL DIABETES FEDERATION. 2021. In: Diabetes facts & figures. Disponível em: https://www.idf.org/aboutdiabetes/what-is-diabetes/facts-figures.html. Acessado em: 31 de maio de 2022.
KOW CS e HASAN SS. Mortality risk with preadmission metformin use in patients with COVID-19 and diabetes: a meta-analysis. Journal of Medical Virology, 2021; 93(2): 695-697.
LALLY MA, et al. Metformin is associated with decreased 30-day mortality among nursing home residents infected with SARS-CoV2. Journal of the American Medical Directors Association, 2021; 22(1): 193-198.
LIMA-MARTÍNEZ MM, et al. COVID-19 y diabetes mellitus: una relación bidireccional. Clinica e Investigacion en Arteriosclerosis, 2021; 33(3): 151-157.
LI J, et al. Metformin Use in Diabetes Prior to Hospitalization: Effects on Mortality in Covid-19, 2020; 26(10):1166-1172.
LUKITO AA, et al. The effect of metformin consumption on mortality in hospitalized COVID-19 patients: a systematic review and meta-analysis. Diabetes & Metabolic Syndrome: Clinical Research & Reviews, 2020; 14(6): 2177-2183.
LUO P, et al. Metformin treatment was associated with decreased mortality in COVID-19 patients with diabetes in a retrospective analysis. The American journal of tropical medicine and hygiene, 2020; 103(1): 69-72.
NAPOLEÃO RNMA, et al. COVID-19: Compreendendo a “tempestade de citocinas”. Research, Society and Development, 2021; 10(5): 1-12.
OH TK, SONG I. Metformin use and risk of COVID-19 among patients with type II diabetes mellitus: an NHIS-COVID-19 database cohort study. Acta diabetologica, 2021; 58(6): 771-778.
POLY TN, et al. Metformin use is associated with decreased mortality in COVID-19 patients with diabetes: evidence from retrospective studies and biological mechanism. Journal of clinical medicine, 2021; 10(16): 1-13.
SCHEEN AJ. Metformin and COVID-19: from cellular mechanisms to reduced mortality. Diabetes & Metabolismo, 2020; 46(6): 423-426.
SHARMA S, et al. Metformin in COVID-19: a possible role beyond diabetes. Diabetes Research and Clinical Practice, 2020; 164(2020): 1-3.
SINGH AK, SINGH R. Is metformin ahead in the race as a repurposed host-directed therapy for patients with diabetes and COVID-19? Diabetes Research and Clinical Practice, 2020; 165(2020): 1-4.
SOUZA AKA, et al. Fármacos para o tratamento do diabetes mellitus tipo 2: interferência no peso corporal e mecanismos envolvidos. Rev Ciênc. Med, 2021; 30(2021): 1-11.
TAMURA RE, et al. Outcome and death risk of diabetes patients with Covid-19 receiving pre-hospital and in-hospital metformin therapies. Diabetology & Metabolic Syndrome, 2021; 13(1): 1-13.
VARGHESE E, et al. Diabetes and coronavirus (SARS-CoV-2): Molecular mechanism of Metformin intervention and the scientific basis of drug repurposing. PLoS Pathogens, 2021; 17(6): 1-20.
WIERNSPERGER N, et al. Protection by metformin against severe Covid-19: An in-depth mechanistic analysis. Diabetes & Metabolismo, 2022; 48(4): 1-12.
WONG CKH, et al. Metformin Use in Relation to Clinical Outcomes and Hyperinflammatory Syndrome Among COVID-19 Patients With Type 2 Diabetes: A Propensity Score Analysis of a Territory-Wide Cohort. Frontiers in Endocrinology, 2022 13(810914): 1-10.
WORLD HEALTH ORGANIZATION. 2022. WHO Coronavirus (COVID-19) Dashboard. Disponível em: https://covid19.who.int/. Acessado em: 31 de maio de 2022.
YANG W, et al. The effect of metformin on mortality and severity in COVID-19 patients with diabetes mellitus. Diabetes Research and Clinical Practice, 2021; 178(2021): 1-8.
ZANGIABADIAN M, et al. The efficacy and potential mechanisms of metformin in the treatment of COVID-19 in the diabetics: a systematic review. Frontiers in Endocrinology, 2021; 12(645194): 1-9.